More than two years have passed since the beginning of the coronavirus disease 2019 (COVID-19) pandemic. Extensive efforts have been invested into better understanding the pathogenesis of this disease and developing the ideal pharmacological approach [1]. However, severe COVID-19 still remains a therapeutic challenge. Since the very beginning of the pandemic, a detrimental inflammatory response was implicated as the major driver of the significant morbidity and mortality that characterizes patients with critical COVID-19 [2].